Skip to main content

Loading market data...

NAMS

NewAmsterdam Pharma Company N.V.

NASDAQ • United states

$21.49

-$0.01

(-0.05%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Management
Credibility
Score

NewAmsterdam Pharma Company N.V. (NAMS)

Unavailable

Quotes may be delayed

$2.57B

Market Cap

1,252,575

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

NewAmsterdam Pharma Company N.V. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: GOOIMEER 2-35, NARRDEN, P7
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

29 Sep 2026

NewAmsterdam Pharma Company N.V. reported Another company event

NewAmsterdam Pharma Company N.V. filed an 8-K covering another company event, supporting financial statements or exhibits.

22 Sep 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in NewAmsterdam Pharma Company N.V..

21 Sep 2026

NewAmsterdam Pharma Company N.V. reported Another company event

NewAmsterdam Pharma Company N.V. filed an 8-K covering another company event.

14 Aug 2026

NewAmsterdam Pharma Company N.V. reported A director or senior management change or compensation event

NewAmsterdam Pharma Company N.V. filed an 8-K covering a director or senior management change or compensation event.

6 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in NewAmsterdam Pharma Company N.V..

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$424.15M

Total assets (USD)$704.45M

Total liabilities (USD)$73.03M

Shareholders' equity (USD)$631.42M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$3.70M	−$64.86M	−$64.14M	−$0.52	10-Q · 5 Aug 2026
Q1 2026	$3.04M	−$58.42M	−$48.44M	−$0.40	10-Q · 7 May 2026
Q4 2025	$32,000	−$65.98M	−$74.10M	Unavailable	10-K · 18 Feb 2026
Q3 2025	$348,000	−$55.14M	−$72.01M	−$0.61	10-Q · 5 Nov 2025
Q2 2025	$19.15M	−$35.64M	−$17.36M	−$0.15	10-Q · 6 Aug 2025
Q1 2025	$2.98M	−$68.93M	−$39.53M	−$0.34	10-Q · 8 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $53.00

146.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

10

⏸️

Hold

0

📉

Sell

0

10 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 23:48 UTC Targets range 42.00–60.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

30

Sep 2026

Kastelein Johannes Jacob Pieter

Director, Chief Scientific Officer

Option exercise

Unavailable per share

50,246 shares

30

Sep 2026

Kastelein Johannes Jacob Pieter

Director, Chief Scientific Officer

Open-market sale

$25.03 per share

50,246 shares

14

Sep 2026

Davidson Michael H.

Director, Chief Executive Officer

Open-market purchase

$22.65 per share

10,000 shares

4

Sep 2026

Smither John W

Director

Open-market sale

$25.32 per share

1,600 shares

1

Sep 2026

Gunning Robert William

Vice President, Controller

Grant or award

Unavailable per share

3,200 shares

24

Aug 2026

Kastelein Johannes Jacob Pieter

Director, Chief Scientific Officer

Option exercise

Unavailable per share

125,000 shares

24

Aug 2026

Kastelein Johannes Jacob Pieter

Director, Chief Scientific Officer

Open-market sale

$26.91 per share

125,000 shares

20

Jul 2026

Kooij Louise Frederika

Chief Accounting Officer

Option exercise

$11.34 per share

105,000 shares

20

Jul 2026

Kooij Louise Frederika

Chief Accounting Officer

Open-market sale

$30.34 per share

105,000 shares

22

Jun 2026

Kooij Louise Frederika

Chief Accounting Officer

Option exercise

$11.28 per share

40,000 shares

Top Shareholders

Frazier Life Sciences Management, L.P.

18,088,902 shares

6.758% change

6/30/2026

Capital World Investors

12,230,557 shares

10.096% change

6/30/2026

Fmr Llc

10,339,663 shares

17.954% change

6/30/2026

Ra Capital Management, L.P.

9,550,191 shares

0% change

6/30/2026

Fcpm Iii Services B.V.

8,490,353 shares

-7.703% change

6/30/2026

Deerfield Management Company, L.P.

4,264,789 shares

0% change

6/30/2026

Viking Global Investors Lp

4,203,567 shares

0% change

6/30/2026

Bain Capital Life Sciences Investors, Llc

3,806,566 shares

-47.902% change

6/30/2026

Maverick Capital Ltd

3,267,802 shares

49.46% change

6/30/2026

Duquesne Family Office Llc

3,070,146 shares

0% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 23:49 UTC· 8 hours ago

Research coverage and investment tools

NewAmsterdam Pharma Company N.V. (NAMS) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$21.49 on 21 Oct 2026. That is 8% of the way from its 52-week low of US$19.58 to its 52-week high of US$42.21. Its market capitalisation was US$2.57 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$3.70M	−$64.86M	−$64.14M	−$0.52	—	-1,752.6%	—	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$3.04M	−$58.42M	−$48.44M	−$0.40	—	-1,921.7%	—	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$32,000	−$65.98M	−$74.10M	Unavailable	—	-206,187.5%	—	10-K · 18 Feb 2026 (opens in a new tab)
Q3 2025	$348,000	−$55.14M	−$72.01M	−$0.61	—	-15,845.7%	—	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$19.15M	−$35.64M	−$17.36M	−$0.15	—	-186.1%	—	10-Q · 6 Aug 2025 (opens in a new tab)
Q1 2025	$2.98M	−$68.93M	−$39.53M	−$0.34	—	-2,314.5%	—	10-Q · 8 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/5/2026	−$0.52	−$0.48	-8.3%
Mar 2026	5/7/2026	−$0.40	−$0.46	+13.0%
Dec 2025	2/18/2026	−$0.63	−$0.40	-57.5%
Sep 2025	11/5/2025	−$0.41	−$0.38	-7.9%

Cash and equivalents: $424.15M
Total assets: $704.45M
Total liabilities: $73.03M
Shareholders' equity: $631.42M

8-K · 29 Sep 2026

NewAmsterdam Pharma Company N.V. reported Another company event (opens in a new tab)

NewAmsterdam Pharma Company N.V. filed an 8-K covering another company event, supporting financial statements or exhibits.
SCHEDULE 13D/A · 22 Sep 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in NewAmsterdam Pharma Company N.V..
8-K · 21 Sep 2026

NewAmsterdam Pharma Company N.V. reported Another company event (opens in a new tab)

NewAmsterdam Pharma Company N.V. filed an 8-K covering another company event.
8-K · 14 Aug 2026 · Management change

NewAmsterdam Pharma Company N.V. reported A director or senior management change or compensation event (opens in a new tab)

NewAmsterdam Pharma Company N.V. filed an 8-K covering a director or senior management change or compensation event.
SCHEDULE 13G/A · 6 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in NewAmsterdam Pharma Company N.V..

Insider	Date	Transaction	Shares	Average price	Filing
Kastelein Johannes Jacob Pieter Director, Chief Scientific Officer	30 Sep 2026	Option exercise (M)	+50,246	—	Form 4 (opens in a new tab)
Kastelein Johannes Jacob Pieter Director, Chief Scientific Officer	30 Sep 2026	Open-market sale (S)	−50,246	$25.03	Form 4 (opens in a new tab)
Davidson Michael H. Director, Chief Executive Officer	14 Sep 2026	Open-market purchase (P)	+10,000	$22.65	Form 4 (opens in a new tab)
Smither John W Director	4 Sep 2026	Open-market sale (S)	−1,600	$25.32	Form 4 (opens in a new tab)
Gunning Robert William Vice President, Controller	1 Sep 2026	Grant or award (A)	+3,200	—	Form 4 (opens in a new tab)
Kastelein Johannes Jacob Pieter Director, Chief Scientific Officer	24 Aug 2026	Option exercise (M)	+125,000	—	Form 4 (opens in a new tab)
Kastelein Johannes Jacob Pieter Director, Chief Scientific Officer	24 Aug 2026	Open-market sale (S)	−125,000	$26.91	Form 4 (opens in a new tab)
Kooij Louise Frederika Chief Accounting Officer	20 Jul 2026	Option exercise (M)	+105,000	$11.34	Form 4 (opens in a new tab)
Kooij Louise Frederika Chief Accounting Officer	20 Jul 2026	Open-market sale (S)	−105,000	$30.34	Form 4 (opens in a new tab)
Kooij Louise Frederika Chief Accounting Officer	22 Jun 2026	Option exercise (M)	+40,000	$11.28	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Frazier Life Sciences Management, L.P.	6/30/2026	18,088,902	6.758%
Capital World Investors	6/30/2026	12,230,557	10.096%
Fmr Llc	6/30/2026	10,339,663	17.954%
Ra Capital Management, L.P.	6/30/2026	9,550,191	0%
Fcpm Iii Services B.V.	6/30/2026	8,490,353	-7.703%
Deerfield Management Company, L.P.	6/30/2026	4,264,789	0%
Viking Global Investors Lp	6/30/2026	4,203,567	0%
Bain Capital Life Sciences Investors, Llc	6/30/2026	3,806,566	-47.902%
Maverick Capital Ltd	6/30/2026	3,267,802	49.46%
Duquesne Family Office Llc	6/30/2026	3,070,146	0%

Previous close: 21.50 USD
Day range: 21.31 – 22.28 USD
52-week range: 19.58 – 42.21 USD
Volume: 1,252,575
Market cap: $2.57B
Average volume: 1,469,930
EPS (FY 2025, diluted): −1.72 USD
Shares outstanding: 119.54M
Beta (5Y monthly): 0.11

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 11 hours ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:23 UTC· 1 hour ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for NAMS yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.